Literature DB >> 18480630

Transobturator tape in the management of female stress incontinence: clinical outcomes at medium term follow-up.

E Kocjancic1, S Crivellaro, I A Oyama, A Singla, S Ranzoni, R Carone, A Manassero, P Gontero, B Frea.   

Abstract

OBJECTIVE: To assess the efficacy of transobturator tape (TOT) in the management of stress urinary incontinence at a medium term follow-up.
METHODS: TOT is a polypropylene tape positioned through the obturator foramen. 70 patients with type II urinary stress incontinence were treated with TOT between June 2003 and May 2006. Patients were prospectively studied by physical examination, quality of life questionnaire (I-QOL), visual analog scale, global impression (dry, improved, same, worse), preoperative urodynamic study, and pre- and postoperative flowmetry. Statistical analysis (t test) of the difference in I-QOL scores and flowmetry was made by StatSoft V. 5.1.
RESULTS: The average follow-up was 32 (range 12-48) months. The I-QOL score increased statistically significantly by 40 points. The average percent improvement was 80%. 90% (63/70) of the patients were dry and 5% (4/70) were improved. The pre- and postoperative uroflowmetry studies were not statistically different. Vaginal erosion occurred in 4 patients.
CONCLUSION: TOT is a safe procedure with a good efficacy at 32-month follow-up. 2008 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2008        PMID: 18480630     DOI: 10.1159/000127340

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  2 in total

1.  Impact of the midurethral sling procedure on quality of life in women with urinary incontinence.

Authors:  Hwa Su Lim; Jong Min Kim; Phil Hyun Song; Hyun Tae Kim; Hee Chang Jung
Journal:  Korean J Urol       Date:  2010-02-19

Review 2.  Safety considerations for synthetic sling surgery.

Authors:  Jerry G Blaivas; Rajveer S Purohit; Matthew S Benedon; Gabriel Mekel; Michael Stern; Mubashir Billah; Kola Olugbade; Robert Bendavid; Vladimir Iakovlev
Journal:  Nat Rev Urol       Date:  2015-08-18       Impact factor: 14.432

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.